Mast Therapeutics, Inc. SVRA 深 滬
等待開盤 10-09 09:30:00 美东时间
3.47
+0.040
+1.17%
華盛通- 最 高3.53
- 今 開3.45
- 成交量 133.06万股
- 最 低 3.34
- 昨 收 3.43
- 總市值 6.00亿
- 52周最高 4.295
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 1.89
- 委 比 -48.33%
- 總股本 1.73亿
- 歷史最高 17.187
- 量 比 1.48
- 振 幅 5.54%
- 歷史最低 0.69
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Savara Presents New Data From Phase 3 IMPALA-2 Showing Molgramostim Beneficial In aPAP Patients Regardless Of Disease Severity
– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –– Changes in DLco%, the Primary Endpoint in IMPALA-2, Were Significantly Correlated
09-29 15:22
Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy
In a dramatic turn of events, Savara Inc. is facing a class action lawsuit that...
09-12 04:15
HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $5 to $8.
09-03 22:36
Savara Highlights MOLBREEVI Development in New Presentation
The latest announcement is out from Savara ( ($SVRA) ). Savara Inc. has updated...
09-02 21:28
Savara upgraded at H.C. Wainwright on potential refiling of marketing application
H.C. Wainwright upgraded Savara (NASDAQ:SVRA) to Buy from Neutral and raised its price target to $5 from $2 per share on Friday, citing a potential resubmission of the company’s marketing application ...
08-16 03:09
HC Wainwright & Co. Upgrades Savara to Buy, Raises Price Target to $5
HC Wainwright & Co. analyst Andrew S. Fein upgrades Savara (NASDAQ:SVRA) from Neutral to Buy and raises the price target from $2 to $5.
08-15 21:09
Savara Re-elects Board Members at Annual Meeting
Savara ( ($SVRA) ) has provided an announcement. On June 5, 2025, Savara Inc. h...
06-07 05:23
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares rose 60.0% to $0.64 during Tuesday's regul...
05-28 01:05
